Kiniksa Pharmaceuticals Ltd expected to post a loss of 65 cents a share - Earnings Preview

Kiniksa Pharmaceuticals International

01/11/2021 04:38

* Kiniksa Pharmaceuticals Ltd  KNSA.OQ   KNSA.O  is expected
to show a rise in quarterly revenue when it reports results on
November 3 (estimated). 
* The Hamilton, Bermuda-based company is expected to report
revenue of $10.176 million, according to the mean estimate from
4 analysts, based on Refinitiv data.  
​* Refinitiv's mean analyst estimate for Kiniksa Pharmaceuticals
Ltd is for a loss of 65 cents per share. For the same quarter
last year, the company reported a loss of 66 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for Kiniksa
Pharmaceuticals Ltd is $30​, about 65.4% above​ its last closing
price of $10.39. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Jun. 30 2021  -0.94       -0.79      -0.61     Beat    23
 Mar. 31 2021  -0.63       -0.72      -0.72     Met     0.7
 Dec. 31 2020  -0.61       -0.62      -0.79     Missed  -26.9​
 Sep. 30 2020  -0.60       -0.60      -0.66     Missed  -9.1
 Jun.          -0.60​      -0.63      -0.65     Missed  -3.8​
 30​ 2020​                                              
 Mar. 31 2020  -0.67       -0.63      -0.48     Beat    24.3​
 Dec. 31 2019  -0.64       -0.62      -0.58     Beat    6.5
 Sep. 30 2019  -0.74       -0.72      -0.49     Beat    31.7
 This summary was machine generated November 1 at 04:38 GMT.  All
figures in US dollars unless otherwise stated